ArticleFrontiers in chemistry2026
Green-synthesized rhein-selenium nanoparticles exhibit potent and highly selective anticancer activity against colon cancer via apoptosis and gene regulation.
Article in Frontiers in chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Colon cancer remains a major global health challenge, necessitating the development of novel, selective, and sustainable therapeutic strategies. Rhein, a bioactive anthraquinone isolated from Cassia italica, has demonstrated anticancer potential but suffers from limited bioavailability. To overcome these limitations, we investigated the green biosynthesis of Rhein-selenium nanoparticles (Rh-Se-NPs) and evaluated their anticancer efficacy. Methods: Rhein was extracted from Cassia italica leaves and confirmed by 1H and 13C nuclear magnetic resonance spectroscopy. Rh-Se-NPs were synthesized via a green biosynthetic approach and characterized using transmission electron microscopy (TEM), dynamic light scattering (DLS), and zeta potential analysis. Cytotoxicity was assessed against DLD-1 and SW620 colon cancer cell lines, with FSU fibroblast cells serving as controls. Cell proliferation, migration, and apoptosis were evaluated through morphological analysis, wound healing assays, caspase activity measurements, and gene expression profiling of oncogenes and tumor suppressors. Results and Discussion: Rh-Se-NPs exhibited spherical morphology (32 ± 5 nm, TEM), a hydrodynamic diameter of 90.4 nm (DLS), and high colloidal stability (zeta potential: 31.1 mV). Compared to free Rhein, Rh-Se-NPs demonstrated significantly enhanced cytotoxicity, reducing IC50 values by more than two-fold and increasing selectivity indices to 12.85 (DLD-1) and 6.93 (SW620). Functional assays confirmed inhibition of cell proliferation and migration. Apoptosis was evidenced by elevated caspase-9 and caspase-3 activities. Gene expression analysis revealed strong downregulation of oncogenes (CEA, FOXQ1, CXCL17, VEGFA) and marked upregulation of the tumor suppressor PTEN (up to 15.9-fold). This study demonstrates, for the first time, that Rh-Se-NPs act as a biocompatible phytochemical-selenium nanoplatform with dual anticancer mechanisms: apoptosis induction and oncogene suppression. The findings highlight Rh-Se-NPs as a promising, sustainable, and highly selective therapeutic strategy for colon cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.